Ceriello, A., Ofstad, A. P., Zwiener, I., Kaspers, S., George, J., & Nicolucci, A. (2020). Empagliflozin reduced long-term HbA1c variability and cardiovascular death: Insights from the EMPA-REG OUTCOME trial. Cardiovasc Diabetol.

Ceriello, Antonio, Anne Pernille Ofstad, Isabella Zwiener, Stefan Kaspers, Jyothis George, and Antonio Nicolucci. "Empagliflozin Reduced Long-term HbA1c Variability and Cardiovascular Death: Insights From the EMPA-REG OUTCOME Trial." Cardiovasc Diabetol 2020.

Ceriello, Antonio, et al. "Empagliflozin Reduced Long-term HbA1c Variability and Cardiovascular Death: Insights From the EMPA-REG OUTCOME Trial." Cardiovasc Diabetol 2020.